Crosstalk between Pancreas’ Alpha and Beta Cells May Reveal New Targets for Diabetes Treatment
American Physiological Society (APS)
Scientists have developed a qubit platform formed by freezing neon gas into a solid, spraying electrons from a light bulb’s filament onto it, and trapping a single electron there. This system shows great promise as an ideal building block for quantum computers.
Adaptable and versatile, molecular qubits hold promise for numerous quantum applications. By altering the qubit's host environment, a team supported by the Q-NEXT quantum center has extended the length of time these qubits can maintain information.
VLA teams up with Juno spacecraft to study Jupiter's atmosphere, and ALMA reveals new details about Io's volcanoes.
Dos artículos científicos publicados recientemente muestran cómo estos telescopios están ayudando a la comunidad científica a conocer mejor el planeta más grande de nuestro sistema solar, Júpiter, y su luna más cercana, Io.
A ToxSpotlight article in the November 2022 issue of ToxSci assesses the mechanism for cellular accumulation of diglycolic acid while another explores the effect of long-term St. John’s wort administration on acetaminophen-induced acute hepatotoxicity and the involved mechanisms.
A study of 50 adult patients with cystic fibrosis (CF) has found that challenged urine bicarbonate excretion may offer a new, simple, and safe quantification of cystic fibrosis transmembrane conductance regulator (CFTR) function and the extent of its pharmacologic improvement. The study is published in Annals of Internal Medicine.
An analysis of the CHANCE-2 trial has found that persons with normal renal function receive greater benefit from antiplatelet therapy with ticagrelor–aspirin versus clopidogrel–aspirin. The analysis is published in Annals of Internal Medicine.
A multinational cohort study of persons with atrial fibrillation (AF) found that compared with all direct oral anticoagulants (DOACs), apixaban was associated with lower rates of gastrointestinal (GI) bleeding but similar rates of ischemic stroke, intracranial hemorrhage (ICH), and all-cause mortality. The findings are published in Annals of Internal Medicine.
Among outpatients with mild to moderate COVID-19, treatment with ivermectin, compared with placebo, did not significantly improve time to recovery in this trial that enrolled more than 1,500 participants in the United States.
The symptoms reported after administration of the Pfizer-BioNTech COVID-19 vaccine were comparable overall to those for approved non–SARS-CoV-2 vaccines in this study including 7,800 children younger than age 5.